TARGETABLE ONCOGENES (EGFR, ALK, ROS1)

Clinical trials for TARGETABLE ONCOGENES (EGFR, ALK, ROS1) explained in plain language.

Never miss a new study

Get alerted when new TARGETABLE ONCOGENES (EGFR, ALK, ROS1) trials appear

Sign up with your email to follow new studies for TARGETABLE ONCOGENES (EGFR, ALK, ROS1), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

Precision radiation zaps tumors in advanced lung cancer trial

Disease control Completed

This study tested whether adding a precise form of radiation therapy to standard targeted drug treatment could better control advanced lung cancer. It involved 27 people with stage IV non-small cell lung cancer driven by specific gene mutations who were already responding to thei…

Matched conditions: TARGETABLE ONCOGENES (EGFR, ALK, ROS1)

Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control

Last updated Mar 30, 2026 14:30 UTC

TARGETABLE ONCOGENES (EGFR, ALK, ROS1)

Get alerted when new TARGETABLE ONCOGENES (EGFR, ALK, ROS1) trials appear

Precision radiation zaps tumors in advanced lung cancer trial